Quizartinib

Quizartinib (Vanflyta®) is a highly potent, selective, oral, second-generation, type 2 FLT3 inhibitor specifically targeting the internal tandem duplication (FLT3-ITD) mutation. In the landscape of Acute Myeloid Leukemia (AML), it is distinguished from midostaurin by its specificity for the ITD mutation rather than covering both ITD and TKD variants.

Clinical Indication and Efficacy

• Indication: It is FDA-approved for use in adults with newly diagnosed FLT3-ITD-positive AML.
• Evidence: In the Phase 3 QuANTUM-First trial, adding quizartinib to standard “7+3” induction and consolidation chemotherapy significantly improved median overall survival (OS) to 31.9 months compared to 15.1 months for the placebo arm.
• Protocol Integration: It is administered during the induction phase (starting after chemotherapy), continued during consolidation with high-dose cytarabine (HiDAC), and then utilized as single-agent maintenance therapy for up to three years.

Safety and Pharmacist Monitoring

For board preparation, the safety profile and regulatory requirements are high-yield:

• Boxed Warnings: It carries a Black Box Warning for QT interval prolongation, torsades de pointes, and cardiac arrest.
• REMS Program: Due to these cardiac risks, quizartinib is only available through a restricted distribution program called the Vanflyta REMS.
• Myelosuppression: Patients often experience prolonged and severe neutropenia and thrombocytopenia compared to standard chemotherapy alone.
• Drug-Drug Interactions: Quizartinib is a major CYP3A4 substrate. You must dose-reduce quizartinib when it is used concomitantly with strong CYP3A4 inhibitors (e.g., posaconazole) and avoid use with strong or moderate CYP3A4 inducers.
• Cardiac Monitoring: Baseline and periodic ECGs are mandatory, and pharmacists should screen for other concurrent QT-prolonging medications to mitigate the risk of additive toxicity.